Operating income
−$18M
Free cash flow
−$6M
Trailing 12 months
Propanc Biopharma, Inc.
PPCB
About Propanc Biopharma
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertakes the research activities for the POP1 Program and the University of Granada to develop a synthetic recombinant version of PRP. Propanc Biopharma, Inc. was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. The company was incorporated in 2007 and is based in Camberwell, Australia.
Leadership
- Jeaninne ZimmermanChief Financial Officer
- James NathanielszChief Executive Officer, Director
- Employees
- 1
- Business address
- CAMBERWELL, VICTORIA, C3
- Fiscal year ends
- June 30
- Listed
- Nasdaq · PPCB
Share price
Daily closing price. The header shows the latest close, the market cap at that close and the change over the selected range. Hover or tap the chart to read any day.
$0.49
−$49.01 (−99.01%)past year
- Market cap
- $1M
- At close
- Oct 6, 2026
Share price vs index
Propanc Biopharma's share price and the index, each as its percentage change since the first day of the selected range. The shading shows the gap: green while Propanc Biopharma is ahead, orange while it is behind. The values at the end are each one's change over the range.
Income statement
Revenue, gross profit and net income
Q4 26
Revenue, gross profit and net income on one scale, so their sizes can be compared period by period.
Operating leverage
Q4 26
Revenue growth against operating expense growth, each against the same quarter a year earlier. While revenue grows faster than opex, each extra dollar of sales keeps more profit.
Cash flow
Operating and free cash flow
Q4 26
Free cash flow is what is left of operating cash flow after capital expenditure. The gap between each pair of bars is that year's capex.
Cash flow statement
Q4 26
The reported movements behind the change in cash in the chosen year or quarter. Solid bars are totals; hatched bars are what was added or taken off between them.
TotalAddedSubtracted
Capital allocation
Q4 26
Operating cash flow above zero; what it was spent on below: capital expenditure, dividends and buybacks.
Stock-based compensation
Q4 26
Stock-based compensation reported in the cash flow statement each period. The line is that amount as a percentage of the same period's revenue.
Stock-based compensation
Balance sheet
Assets, liabilities and equity
Q4 26
The balance sheet at the end of the chosen year or quarter. What the company owns on the left, against what it owes and what belongs to shareholders on the right. Both columns add up to total assets.
War chest
Q4 26
Cash and short-term investments held at each quarter end. The figure at the top of each column is the total.